ABSTRACT-We sought to approach a practical question: Should polymyxins be used in the initial empirical antibiotic regimen in the intensive care unit (ICU) patient with fever that is thought to be due to infection? By retrieving data from the literature and the WHONET Greece, we formulated a mathematical model to estimate the probability (P total ) that a gramnegative bacterium susceptible only to polymyxins is isolated from an ICU patient. P total = P 1 * P 2 * P 3 * P 4 , where P total = total probability; P 1 = probability that fever is due to infection; P 2 = probability that infection is due to gram-negative bacteria; P 3 = probability that the gram-negative bacterium is Acinetobacter baumannii, Pseudomonas aeruginosa, or Klebsiella pneumoniae; and P 4 = probability that A. baumannii, P. aeruginosa, or K. pneumoniae is susceptible only to polymyxins. Using the information from our data sources, we estimated that P 1 (before physician input in differential diagnosis) = 0.5, P 2 = 0.523, P 3 = 0.79, and P 4 = 0.567, thus P total = P 1 * P 2 * P 3 * P 4 = 0.5 * 0.523 * 0.79 * 0.567 = 0.117 = 11.7%. Based on this information and combining it with data regarding the attributable mortality of inappropriate empirical antimicrobial treatment, 4 to 5 patients in every 100 ICU patients will die if physicians do not include polymyxins in the initial empirical regimen in the ICU setting for an episode of fever due to infection. Polymyxins should probably be included in the empirical antibiotic regimen in the ICU setting in hospitals, where the observed probability that a gram-negative bacterium (A. baumannii, P. aeruginosa, or K. pneumoniae) is polymyxin-only-susceptible is close to that (50%) used in our model (based on the individual hospital data).
INTRODUCTION
Ideally, a rapid microbiological identification of the offending pathogen and its antibiotic susceptibility profile performed for every patient with infection could offer the opportunity for etiological treatment. As technology does not always permit and resources are limited, empirical antibiotic therapy remains a mainstay for the treatment of many patients with infection. Delay in instituting the appropriate antibiotics for infections poses risk to the patient's life (1) . This is particularly so in the intensive care unit (ICU) setting, where sepsis remains one of the most important causes of mortality worldwide. The international consensus regarding the treatment of sepsis stresses the early institution of correct antimicrobial therapy (2) .
Infections due to gram-negative bacteria including Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae have become common in critically ill patients in many parts of the world. Because multidrug resistance of these bacterial pathogens is of particular concern, the intravenous use of polymyxins reemerged worldwide (3) . It is noteworthy that bacteremia due to A. baumannii managed with inappropriate therapy is associated with increased mortality (4Y7).
Subsequently, physicians have to decide when to institute therapy with polymyxins. Thus, we used a decision analysis approach to try to evaluate when polymyxins should be included in the empirical antibiotic regimen in critically ill patients with fever.
METHODS

Definitions of probabilities
We sought to construct a useful mathematical model to determine the probability P total that stands for the total probability of isolation from an ICU patient of a gramnegative pathogen belonging to the species A. baumannii, P. aeruginosa, or K. pneumoniae that will be resistant to carbapenems and will be the cause of an episode of fever due to infection in the ICU environment. The equation from which this probability is derived is: P total = P 1 * P 2 * P 3 * P 4 , where P 1 = probability that fever is due to infection; P 2 = probability that infection is due to gram-negative bacteria; P 3 = probability that gram-negative bacteria is A. baumannii, P. aeruginosa, or K. pneumoniae; and P 4 = probability that the isolated A. baumannii, P. aeruginosa, or K. pneumoniae is susceptible only to polymyxins.
Data collection
We collected data from the literature (8Y12) to estimate the probability P 1 . We collected data from the WHONET Greece (Data for all ICU clinical specimens in the period January 2005 through June 2005 from the Greek System for the surveillance of antimicrobial resistance) (13) (http://www.mednet.gr/whonet) and from recent data from the SENTRY antimicrobial surveillance program (14) to estimate the P 2 , P 3 , and P 4 probabilities for A. baumannii, P. aeruginosa, or K. pneumoniae.
RESULTS
The probability P 1 that a fever, before physician's input in differential diagnosis, is due to an infection is approximately 50% (i.e. P 1 = 0.5). After physician's input (thorough history and examination accompanied by targeted tests (10, 12) ), theP 1 , if quick well-standardized laboratory measurements of cytokines and certain growth factors will be available (15Y17). Regarding the probabilities P 2 , P 3 , and P 4 , we retrieved data from the WHONET Greece to estimate the relevant values. Specifically, among 5,958 bacterial isolates from clinical specimens of patients in the ICU setting from various hospitals in Greece during the period January 2005 through June 2006, gram-negative isolates constituted 3,117 (52.3%) (i.e., P 2 = 0.523). Among these gram-negative isolates, the probability that one belonged to the species A. baumannii, K. pneumoniae, or P. aeruginosa was 2,468/3,117 = 0.79 (i.e., P 3 = 0.79). The length of stay in hospital and the ICU and the courses of antibiotics a patient had have a significant role on the probabilities that a patient will have a multidrug resistant gram-negative bacterium as a cause of ICU fever (i.e., they will affect P 2 , P 3 , and P 4 ). P 4 is the probability that a gram-negative bacterium belonging to the species A. baumannii, P. aeruginosa, or K. pneumoniae is susceptible only to polymyxins, often the last resort for the treatment of multidrug resistant bacterial infections. This probability was derived from data on the in vitro antimicrobial susceptibility profile of the above gramnegative pathogens to polymyxins and carbapenems. Susceptibility to colistin (polymyxin E) of A. baumannii blood isolates was 97.8%, which is based on the latest data from WHONET Greece. The proportion of isolates included in the WHONET program in Greece that were resistant to polymyxin E (2.2%) is almost identical to the figure regarding resistance of A. baumannii clinical isolates from different body fluids to polymyxin B reported in the SENTRY program (2.1%) (14) . 50.6% of A. baumannii ICU isolates (blood and nonblood) had susceptibility to ampicillin/sulbactam (sulbactam is not available as a separate medication in Greece), 4.3% to piperacillin/tazobactam, 13.1% to amikacin, and 1.3% to ciprofloxacin. 66.3% of P. aeruginosa ICU isolates (blood and nonblood) are susceptible to piperacillin/tazobactam, 52.5% to amikacin, and 38.3% to ciprofloxacin. 29.5% of K. pneumoniae ICU isolates (blood and nonblood) are susceptible to piperacillin/tazobactam, 25.7% to tobramycin, and 27.9% to ciprofloxacin. Resistance of A. baumannii blood isolates, included in the WHONET program in Greece, to imipenem and meropenem was 67.3% and 32.8%, respectively. Regarding the results of the in vitro susceptibility testing, 67.7%, 62.9%, and 29% of A. baumannii, P. aeruginosa, and K. pneumoniae isolates from all clinical specimens from ICU patients (blood and nonblood isolates) included in the WHONET program in Greece, respectively, were resistant to imipenem. Mechanisms of carbapenem resistance of A. baumannii, P. aeruginosa, or K. pneumoniae isolates include the carriage of metallo-"-Lactamase genes (such as bla VIM-1 , bla VIM-2 , or bla VIM-4 ) and the overexpression of efflux pumps (18Y21). Data from the SENTRY program show that resistance to polymyxins of P. aeruginosa and K. pneumoniae isolates from all clinical specimens (blood and nonblood isolates) from ICU and non-ICU patients was 1.3% and 1.8%, respectively (14) .
Unfortunately, there is lack of data regarding the proportion of carbapenem-resistant A. baumannii, P. aeruginosa, and K. pneumoniae isolates that are also resistant to polymyxins. However, given the very low probability of resistance to polymyxins among A. baumannii, P. aeruginosa, and K. pneumoniae isolates (as shown by the WHONET Greece data as well the SENTRY international data), the proportion of carbapenem-resistant A. baumannii, P. aeruginosa, and K. pneumoniae isolates approximates that of polymyxin-onlysusceptible isolates. The calculation of the proportion of carbapenem-resistant isolates among A. baumannii, P. aeruginosa, and K. pneumoniae isolates included in WHONET Greece was based on the following data: (1, Resistance to carbapenems is usually accompanied by broad resistance to many classes of antibiotics. Therefore, Acinetobacter spp. that are resistant to carbapenems have the following susceptibility pattern according to data from the SENTRY trial: 5.5% of them are susceptible to ceftazidime, 5.3% to cefepime, 8.4% to ampicillin/sulbactam, 6.3% to ciprofloxacin, 22.8% to amikacin, and 97.2% to polymyxin (14) . By assumption, we considered A. baumannii, P. aeruginosa, or K. pneumoniae isolates with resistance to carbapenems to have currently no other therapeutic alternative but polymyxins (hopefully, the use of tigecycline will enforce our armamentarium for carbapenem-resistant A. baumannii and K. pneumoniae isolates). The antimicrobial activity of polymyxins against 54,731 A. baumannii, P. aeruginosa, or K. pneumoniae clinical isolates included in SENTRY was estimated to be 97.9%, 98.2%, and 98.7%, respectively (14) . Thus, for practical reasons, one can accept that polymyxin is effective in 98% against A. baumannii, P. aeruginosa, or K. pneumoniae clinical isolates. We calculated above that the probability of resistance to carbapenems among A. baumannii, P. aeruginosa, or K. pneumoniae isolates (n = 2,468) included in WHONET is 57.9% (0.579). Thus, the percentage of A. baumannii, P. aeruginosa, or K. pneumoniae isolates that are polymyxin-only-susceptible is 0.98 * 0.579 = 0.567 (56.7%).
Based on the above calculations, P 4 is 0.567, and thus, P total = P 1 * P 2 * P 3 * P 4 = 0.5 * 0.523 * 0.79 * 0.567 = 0.117 = 11.7% (in this case, P total refers to the situation where there is no physician input, i.e., the worst-case scenario). This means that in an ICU setting with the probabilities used in our model, in every 100 patients with fever, 11.7 patients will have an A. baumannii, a P. aeruginosa, or a K. pneumoniae isolate that is susceptible only to polymyxins. After a meticulous history and physical examination and targeted tests, the possibility that the patient has indeed infection P 1 would be more than 0.5 and, in the ideal case scenario, will move to 1.0. Hence after physician input, P total = P 1 * P 2 * P 3 * P 4 = 1.0 * 0.523 * 0.79 * 0.567 = 23.4%. It is also likely that an initial physician evaluation could markedly decrease P 2 . For example, a patient admitted to an ICU with a diffuse interstitial pneumonia in the middle of an influenza outbreak is very likely to have an infection (P 1 ), but extremely unlikely to have a gram-negative bacillus as the cause. Moreover, a Gram stain of clinical material in patients presenting with fever in the ICU could rapidly make it a diagnosis of staphylococcal or streptococcal infection, making P 2 very low. Because polymyxins are not effective against grampositive bacteria, one would not consider them in such a case scenario.
In a sensitivity analysis, we used the probability of P 4 as derived from the SENTRY antimicrobial surveillance program. We calculated the total resistance to carbapenems: (2, and divided the sum to the total number of A. baumannii, P. aeruginosa, or K. pneumoniae isolates (n = 17,968). The total resistance to carbapenems equals 0.084. Thus, based on the above calculations and assumptions, P 4 = 0.98 * 0.084 = 0.0784. This means that P total = P 1 * P 2 * P 3 * P 4 = 1.0 * 0.523 * 0.79 * 0.0784 = 0.01611Y0.0322 = 1.61% Y 3.22% [depending on the value of P 1 (0.5Y1)].
In our study, we sought to estimate the mortality associated with the decision not to include polymyxins in the initial empirical antibiotic regimen for the management of patients with infection in the ICU. We calculated that P total = 23.4%. In other words, in every 100 patients treated in the ICU setting in Greece for an episode of fever that is attributed to infection after thoughtful reasoning, approximately 23 (23.4%) patients will have an A. baumannii, a P. aeruginosa, or a K. pneumoniae isolate that is susceptible only to polymyxins. If we accept that there is at least a 15% to 20% (0.15Y0.2) difference in mortality based on the available literature data that are presented above, when we treat infections due to A. baumannii, P. aeruginosa, or K. pneumoniae that are susceptible only to polymyxins, with inappropriate antibiotics versus appropriate antibiotics, then 4 to 5 (3.51Y4.68) patients (23.4 * 0.15 = 3.51 and 23.4 * 0.20 = 4.68) in every 100 patients with fever would die because of our decision not to include polymyxins in the initial empirical regimen in the ICU setting.
In contrast, in our sensitivity analysis using the SENTRY data, we calculated that P total = 3.22% (when P 1 = 1). Therefore, 1 patient (0.48Y0.64) per 100 hospital patients with fever (3.22 * 0.15 = 0.48 and 3.22 * 0.20 = 0.64) with a polymyxin-only-susceptible A. baumannii, P. aeruginosa, or K. pneumoniae isolate would die if polymyxins are not used in the initial empirical antibiotic regimen. It should be emphasized that the SENTRY data refer to clinical isolates from various hospital beds (including regular floor and ICU beds, as there is no such specification in this study (14)).
DISCUSSION
The presence of fever in a patient in the ICU setting is not and should not be considered synonymous with the presence of infection. In fact, data from published studies suggest that in only half of the times is infection the cause of fever in the ICU patient (8Y12). Thus, one has to try to exclude expeditiously noninfectious causes of fever.
Empirical antibiotic treatment after obtaining the necessary cultures needs to be appropriately directed against the most likely pathogen. In a study of 455 consecutive episodes of K. pneumoniae bacteremia, 85 episodes were due to an extended spectrum beta lactamase producing K. pneumoniae. The patients treated with carbapenem for extended spectrum beta lactamase producing K. pneumoniae bacteremia had a lower 14-day mortality (4.8%) than those that received noncarbapenem antibiotics (27.6%). This mortality difference of 22.8% was statistically significant (P = 0.012) (22) . Not only is the administration of the appropriate antibiotics mandatory, but also their timely use. Thirty-day mortality for patients with P. aeruginosa bacteremia treated initially with effective empirical antibiotics was 27.7% vs. 43.4% in the group of patients who received delayed effective antimicrobial treatment (P = 0.079) (1). Thus, delay in instituting effective antibiotic therapy in bacteremia due to P. aeruginosa was associated with mortality higher by 15.7% (although the difference was not statistically significant).
Regarding the attributable mortality of A. baumannii infections, it should be mentioned that some investigators and clinicians suggest that mortality of A. baumannii infections in ICU patients is not directly related to the infection itself, but to comorbidity factors. However, several studies have suggested that there is a higher mortality associated with the use of inappropriate antibiotic therapy in the management of A. baumannii bacteremia (4Y6,23). In three case-control studies, the differences in mortality were higher by 14.3%, 17%, and 26% in the group of cases (patients with A. baumannii bacteremia who received initially inappropriate empirical antimicrobial therapy) than the control group.
From the above-mentioned studies, it seems that mortality is at least 15% higher in a patient with infection due to A. baumannii, P. aeruginosa, or K. pneumoniae when treated with inappropriate empiric antibiotics compared with the mortality when the patient is treated with appropriate antibiotics. In addition, it should be also emphasized that modification of an initially inappropriate empirical antimicrobial regimen does not always improve outcome, probably because the change comes too late to redirect the course of illness (24) .
Although large randomized controlled trials regarding the effectiveness and safety of polymyxins are lacking, the necessity of everyday clinical practice led to their reuse (3). In our study, we sought to estimate the mortality associated with the decision not to include polymyxins in the initial empirical antibiotic regimen for the management of a patient with infection in the ICU setting. We concluded using a decision analysis approach that 3.51 to 4.68 patients in every 100 ICU patients would die because of our decision not to include polymyxins in the initial empirical regimen in this setting. This excess mortality is attributed to the administration of inappropriate empirical antimicrobial therapy to patients with an infection due to A. baumannii, P. aeruginosa, or K. pneumoniae susceptible only to polymyxins. We believe that, based on our analysis, the inclusion of a polymyxin in the initial, empirical antimicrobial regimen of an ICU patient with fever that is thought to be due to infection is justified in a hospital where P 4 is approximately 0.5; that is, the probability that A. baumannii, P. aeruginosa, or K. pneumoniae isolate is susceptible only to polymyxins is approximately 50%.
In contrast, in our sensitivity analysis, we calculated that P total = 0.0322; that is, the probability that an infection is caused by an A. baumannii, a P. aeruginosa, or a K. pneumoniae isolate that is susceptible only to polymyxins is 3.22% in another setting where the possibility of a fever of a patient to be caused by an A. baumannii, a P. aeruginosa, or a K. pneumoniae isolate that is susceptible only to polymyxins is 3.22%. Using these probabilities, 1 patient (0.48Y0.64) per 100 hospital patients would die if polymyxins were not used in the initial empirical antibiotic regimen. It is therefore probably not suggested to include polymyxins empirically in the general hospital setting (outside from the ICU) because their benefit may be jeopardized by their possible disadvantages. On the other hand, some patients in the general hospital setting may benefit from the inclusion of polymyxins in the initial empirical antimicrobial regimen, such as patients with multiple risk factors for an infection due to an isolate that is susceptible only to polymyxins (prolonged hospital stay; previous exposure to multiple classes of antibiotics, especially carbapenems; and presence of multidrug-resistant gramnegative bacteria on previous cultures not deemed to be colonization).
The main disadvantages of the use of polymyxins are their nephrotoxicity (it presents in up to 20% of patients) and their possible role on public health by further inducing antimicrobial resistance. Although nephrotoxicity is a potential drawback, it is usually reversible in the majority of the cases (25) . More randomized clinical trials are needed to evaluate the nephrotoxic potential of polymyxins, but data suggest that their nephrotoxicity profile may be comparable to the nephrotoxic potential of other antibiotic classes such as aminoglycosides and carbapenems (26Y28). A strategy to prevent deterioration of renal function is the appropriate general management of the patient with particular emphasis on fluid and electrolyte abnormalities. Once microbiological data are available, treatment should de-escalate quickly to less aggressive regimens if this is possible. De-escalation therapy will also help to avoid prolonged selective pressure on these bacteria, an issue of importance for public health (24) .
The estimates of the various probabilities in our study were based on several assumptions and published research findings. Thus, the validity of the calculations and subsequently their implications regarding the management of patients in various hospital settings depend on the accuracy of the assumptions made and the research data used. Hence, a limitation of our study is that there are no available data from the SENTRY trial for blood isolates, and subsequently, we could not perform our sensitivity analysis with a focus on patients with bacteremia. In addition, it should be mentioned that different clinicians have a range of beliefs regarding the proportion of acceptable bad outcomes, as it was, for example, observed in a study of infectious disease specialists who participated in a questionnaire study about the management of patients with coagulase-negative staphylococcal blood stream infections (29) .
Physicians often face difficult dilemmas in their practice. After having marched into the era of carbapenems, should we walk further down the road into the era of the reemergence of polymyxins and possibly, in the near future, the tigecycline road for selected infections? Our decision analysis approach suggests that the use of polymyxins is probably justified in the initial, empirical antibiotic regimen for the treatment of patients with infection in the ICU setting, in countries with high probability of infection due to A. baumannii, P. aeruginosa, or K. pneumoniae isolates that are susceptible only to polymyxins (i.e., with a P 4~0 .5). Because this probability (P 4 ) is only 0.07 in the sensitivity analysis we performed with data from the SENTRY study, we would not advocate using polymyxins in clinical settings with a low P 4 . Although the data we used are a constellation of hospital data, one could use the mathematical model we describe to adjust to the particular hospital circumstances to avoid overutilization of polymyxins, antibiotics with an important new role in the management of patients with multidrug resistant gramnegative bacterial infections (30) .
